China-based Innovent Biologics (HKG: 1801) has entered into a partnership with Sanegene Bio USA Inc. to co-develop the small interfering RNA (siRNA) candidate drug SGB-3908 for the treatment of hypertension. Innovent Biologics has secured the exclusive option to license global development, manufacturing, and commercialization rights for the drug. Upon the exercise of these rights, Sanegene will be eligible to receive subsequent research and development milestone payments, sales-based milestone payments, and tiered royalties on future net sales.
SGB-3908, which targets angiotensinogen (AGT), is currently being prepared for an Investigational New Drug (IND) filing.- Flcube.com
